Development of regenerative and advanced therapy medicinal products based on cultured mesenchymal stem cells from umbilical cord
Description: The goal is to develop an advanced therapy medicinal product based on cultured mesenchymal stem cells (MSCs) derived from umbilical cord tissue and intended for treatment of severe immune-mediated diseases and for regenerative medicine. By the 31st October 2019, it will be possible to introduce production of the ATMP based on the developed utility model, functional sample and proven technology. The product will meet principles of Good Manufacturing Practice and requirements of the European Medicines Agency. The use of bioreactor will allow automatization, reproducibility, scalability, and production of cells in numbers sufficient for use in patients involved in clinical trials. During the project, MSCs and their products (lysate, medium) will be delivered to Korean partner.
Amount: CZK 15,240,000
Funding type: research
Funder scheme: TF - DELTA
Start date: 2016-11-01
End date: 2019-10-31
Investigators: Zdeněk Kořístek, Petr Beneš, Zdeněk Kořístek, Petr Beneš, Serhiy Forostyak, Lucie Jurečková, Ján Karkoška, Tomáš Kaško, Stanislava Košková, Radka Koukalová, Tomáš Otevřel, Veronika Pospíšilová, Serhiy Forostyak, Serhiy Forostyak, Serhiy Forostyak, Lucia Knopfová, Petr Kuglík, Jarmila Navrátilová, Karel Souček, Ladislava Vymětalová
Institution: PrimeCell Advanced Therapy, a.s.
Funded outputs count: 1
Funder award ID: TF03000037
OpenAlex ID: G6826224620